Azenta (AZTA) Q3 2026 earnings review
Surprise Revenue Rebound Masks Underlying Cash and Margin Frailty
Azenta delivered a sudden +9% organic revenue spike in Q3, crushing the gloomy sentiment from its Q2 crisis and driving reported revenue to $161M. However, the top-line beat did not translate to the balance sheet. Free cash flow turned negative (-$5M), and Adjusted Gross Margin compressed 140 bps year-over-year due to underutilization and ongoing quality remediation in Automated Stores. Crucially, management's Q4 guidance implies a reversal back into an organic revenue decline, suggesting Q3's strength was heavily aided by timing rather than a permanent structural turnaround.
🐂 Bull Case
After a disastrous Q2 that triggered a $112M impairment, Multiomics posted an 8% organic growth recovery, driven by Next Generation Sequencing and Gene Synthesis. Full-year segment guidance was raised to flat/down 1%.
The long-pending sale of the B Medical Systems business successfully closed on July 1, 2026, injecting cash and allowing management to focus entirely on the core life sciences portfolio turnaround.
🐻 Bear Case
Despite a $161M top-line result, operating cash flow plummeted to $1M, resulting in a Free Cash Flow of -$5M. This contradicts the narrative that the Azenta Business System (ABS) is driving operational efficiency.
Adjusted gross margin dropped 140 bps to 46.2%. The company is still absorbing costs from lower sales volumes and persistent quality remediation and rework activities in Automated Stores.
⚖️ Verdict: ⚪
Mixed. The sudden +9% organic revenue spike provides immediate relief after Q2's crisis, but negative free cash flow, persistent gross margin pressure, and a weak Q4 guide suggest the turnaround remains highly fragile and uneven.
Key Themes
Multiomics Rescue Mission Shows Early Success
Multiomics revenue reached $73M, representing an accelerating 8% organic growth year-over-year. This is a stark reversal from Q2's 2% decline. The rebound was primarily driven by higher revenue in Next Generation Sequencing (NGS) and Gene Synthesis, effectively offsetting the structural, long-term declines in Sanger Sequencing. The rapid stabilization allowed management to raise the segment's full-year outlook.
Sample Management (SRS) Defends the Top Line
Sample Management Solutions (SMS) organic revenue accelerated to 9% growth, heavily supported by the recurring revenue streams of Sample Repository Solutions (SRS) and Consumables and Instruments. This demonstrates the resilience of Azenta's outsourced service model, even as capital equipment sales (Automated Stores) lag.
The Q4 Guidance Disconnect
A major red flag exists between the Q3 results and Q4 outlook. While Q3 posted +9% organic growth, management guided Q4 organic revenue to decline in the low single digits. This rapid deceleration implies that Q3's outperformance was largely a 'dead cat bounce'—likely aided by clearing delayed backlog or isolated timing events—rather than a sustainable demand recovery.
Automated Stores Remediation Drags Margins
Adjusted gross margin decreased by 140 basis points to 46.2%. Management explicitly cited costs related to quality remediation and rework activities in Automated Stores, compounded by unfavorable fixed-cost absorption. The inability to clear these quality hurdles permanently continues to dilute the bottom line.
Free Cash Flow Reversal
Operating cash flow was a meager $1M in Q3, resulting in Free Cash Flow of -$5M after $7M in CapEx. This metric has been decelerating sequentially throughout FY26, dropping from +$15M in Q1 to +$5M in Q2, and now inverting. Generating negative cash flow during a quarter with 12% reported revenue growth raises serious concerns about working capital management.
Challenging Macro Backdrop Continues
CEO John Marotta noted that results were achieved 'despite an uneven and challenging market backdrop.' Capital-intensive spending from biopharma and academic customers remains constrained, creating a ceiling on how fast Azenta's Automated Stores and Cryogenic systems can recover.
Next Generation Sequencing (NGS) Traction
Technological adoption of NGS continues to act as a primary growth engine for Multiomics. As older reading technologies like Sanger Sequencing face technological intermediation, Azenta's investments to scale its NGS footprint are proving critical to maintaining segment relevance.
Other KPIs
Reversing the negative momentum from Q2's dismal $7.8M print. The 11.4% margin represents massive sequential improvement, but it is still down 60 basis points from 12.1% in the prior year period. Management's cost initiatives are fighting against heavy volume absorption headwinds.
The company has repurchased 2.3 million shares against its newly authorized $250 million program. Supported by a healthy cash and marketable securities balance of $529 million, management is actively deploying capital while shares are depressed.
Guidance
Decelerating sharply from Q3's +9% organic growth. This confirms that the Q3 beat was anomalous and the underlying demand environment remains exceptionally challenging heading into the end of the fiscal year.
Accelerating sequentially from Q3's $18.5M. This implies management expects an adjusted EBITDA margin in the 13-14% range on lower sequential revenues, requiring significant cost execution to achieve.
Accelerating from previous guidance of -2% to +1%. The upgrade is largely a mathematical flow-through of the Q3 beat. Multiomics was upgraded from 'down mid-single-digits' to 'down 1% to flat', while SMS remains guided at low-single-digit growth.
Stable. The full-year profit outlook remains unchanged despite the top-line beat in Q3, underscoring the severe margin compression the company has absorbed throughout the year.
Key Questions
The Q4 Disconnect
Organic revenue grew 9% in Q3, yet you are guiding for a low-single-digit decline in Q4. How much of Q3's outperformance was tied to isolated timing events or the clearing of delayed capital orders versus sustainable demand?
Cash Flow Reversal
Despite a massive sequential jump in revenue and Adjusted EBITDA, Free Cash Flow dropped to negative $5M. What were the specific working capital drags this quarter, and what gives you confidence in achieving the 10-15% full-year FCF improvement target?
Automated Stores Quality Issues
You continue to cite quality remediation and rework activities in Automated Stores as a gross margin drag. In Q1, you expected these issues to be resolved by Q2, and in Q2, by Q3. Have these legacy quality issues finally been permanently remediated?